scholarly journals Study of Reversible Platelet Aggregation Model by Nonlinear Dynamics

Mathematics ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 759
Author(s):  
Grigorii A. Vasilev ◽  
Aleksandra A. Filkova ◽  
Anastasia N. Sveshnikova
Keyword(s):  
Nonlinear Dynamics ◽  
Mathematical Model ◽  
Steady State ◽  
Platelet Aggregation ◽  
Mass Action ◽  
Influence Area ◽  
Platelet Aggregate ◽  
Mass Action Law ◽  
Type Node

Blood cell platelets form aggregates upon vessel wall injury. Under certain conditions, a disintegration of the platelet aggregates, called “reversible aggregation”, is observed in vitro. Previously, we have proposed an extremely simple (two equations, five parameters) ordinary differential equation-based mathematical model of the reversible platelet aggregation. That model was based on mass-action law, and the parameters represented probabilities of platelet aggregate formations. Here, we aimed to perform a nonlinear dynamics analysis of this mathematical model to derive the biomedical meaning of the model’s parameters. The model’s parameters were estimated automatically from experimental data in COPASI software. Further analysis was performed in Python 2.7. Contrary to our expectations, for a broad range of parameter values, the model had only one steady state of the stable type node, thus eliminating the initial assumption that the reversibility of the aggregation curve could be explained by the system’s being near a stable focus. Therefore, we conclude that during platelet aggregation, the system is outside of the influence area of the steady state. Further analysis of the model’s parameters demonstrated that the rate constants for the reaction of aggregate formation from existing aggregates determine the reversibility of the aggregation curve. The other parameters of the model influenced either the initial aggregation rate or the quasi-steady state aggregation values.

β3 Tyrosine Phosphorylation in αIIbβ3 (Platelet Membrane GP IIb-IIIa) Outside-in Integrin Signaling

2001 ◽  
Vol 86 (07) ◽  
pp. 246-258 ◽  
Author(s):  
Lisa Nannizzi-Alaimo ◽  
K. S. Srinivasa Prasad ◽  
David Phillips
Keyword(s):  
Platelet Aggregation ◽  
Tyrosine Phosphorylation ◽  
Critical Role ◽  
Clot Retraction ◽  
Signaling Mechanism ◽  
Platelet Aggregate ◽  
Von Willebrand

SummaryThe platelet integrin αIIbβ3 not only binds fibrinogen and von Willebrand factor to mediate platelet aggregation and adhesion, it also serves as a signaling receptor. Platelet agonists such as ADP, thrombin and collagen induce “inside-out” signaling which activates the receptor function of αIIbβ3 for soluble fibrinogen. Subsequent platelet aggregation leads to “outside-in” signaling, inducing platelet aggregate stabilization and triggering a variety of functions important to platelet physiology. This review focuses on the role of β3 tyrosine phosphorylation in αIIbβ3 outside-in signaling. Tyrosine phosphorylation of β3 in platelets is a dynamic process which is initiated upon platelet aggregation and also by adhesion of platelets to immobilized fibrinogen. Tyrosine phosphorylation occurs on the β3 integrin cytoplasmic tyrosine (ICY) domain, a conserved motif found in thesubunits of several integrins. β3 ICY domain tyrosine phosphorylation induces the recruitment of two proteins to the cytoplasmic domains of αIIbβ3: the cytoskeletal protein myosin, important to clot retraction; and the signaling adapter protein Shc, important to platelet stimulation. The critical role of β3 tyrosine phosphorylation to platelet function was established by the diYF mouse, a novel strain which expresses an αIIbβ3 in which the two β3 ICY domain tyrosines have been mutated to phenylalanine. These mice are selectively impaired in outside-in αIIbβ3 signaling, with defective aggregation and clot-retraction responses in vitro, and an in vivo bleeding defect which is characterized by a pronounced tendency to rebleed. Taken together, the data suggest that the β3 tyrosine phosphorylation signaling mechanism is important to αIIbβ3 function and might be applicable to a wide variety of integrin-mediated events.

scholarly journals Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors

2016 ◽  
Vol 61 (3) ◽  
Author(s):  
Elena Lomonosova ◽  
Adam Zlotnick ◽  
John E. Tavis
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Core Protein ◽  
Index Theorem ◽  
Rnase H ◽  
Mass Action ◽  
Significant Activity ◽  
B Virus ◽  
Mass Action Law

ABSTRACT Combination therapies are standard for management of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections; however, no such therapies are established for human hepatitis B virus (HBV). Recently, we identified several promising inhibitors of HBV RNase H (here simply RNase H) activity that have significant activity against viral replication in vitro. Here, we investigated the in vitro antiviral efficacy of combinations of two RNase H inhibitors with the current anti-HBV drug nucleoside analog lamivudine, with HAP12, an experimental core protein allosteric modulator, and with each other. Anti-HBV activities of the compounds were tested in a HepG2-derived cell line by monitoring intracellular core particle DNA levels, and cytotoxicity was assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The antiviral efficiencies of the drug combinations were evaluated using the median-effect equation derived from the mass-action law principle and combination index theorem of Chou and Talalay. We found that combinations of two RNase H inhibitors from different chemical classes were synergistic with lamivudine against HBV DNA synthesis. Significant synergism was also observed for the combination of the two RNase H inhibitors. Combinations of RNase H inhibitors with HAP12 had additive antiviral effects. Enhanced cytotoxicity was not observed in the combination experiments. Because of these synergistic and additive effects, the antiviral activity of combinations of RNase H inhibitors with drugs that act by two different mechanisms and with each other can be achieved by administering the compounds in combination at doses below the respective single drug doses.

scholarly journals Mathematical modeling quantifies ERK-activity in response to inhibition of the BRAFV600E-MEK-ERK cascade

2021 ◽  
Author(s):  
Sara Hamis ◽  
Yury Kapelyukh ◽  
Aileen McLaren ◽  
Colin J. Henderson ◽  
C. Roland Wolf ◽  
...  
Keyword(s):  
Mathematical Model ◽  
Drug Resistance ◽  
Chemical Reactions ◽  
Molecular Mechanisms ◽  
Braf Inhibitor ◽  
Mass Action ◽  
Model Parameters ◽  
Mass Action Kinetics ◽  
Erk Activity

AbstractSimultaneous inhibition of multiple components of the BRAF-MEK-ERK cascade (vertical inhibition) has become a standard of care for treating BRAF-mutant melanoma. However, the molecular mechanisms of how vertical inhibition synergistically suppress intracellular ERK activity, and as a consequence cell proliferation, are yet to be fully elucidated.In this study, we develop a mechanistic mathematical model that describes how the mutant BRAF-inhibitor, dabrafenib, and the MEK-inhibitor, trametinib, affect signaling through the BRAFV600E-MEK-ERK cascade. We formulate a system of chemical reactions that describes cascade signaling dynamics and, using mass action kinetics, the chemical reactions are re-expressed as ordinary differential equations. Using model parameters obtained from in vitro data available in the literature, these equations are solved numerically to obtain the temporal evolution of the concentrations of the components in the signaling cascade.Our mathematical model provides a quantitative method to compute how dabrafenib and trametinib can be used in combination to synergistically inhibit ERK activity in BRAFV600E mutant melanoma cells. This work elucidates molecular mechanisms of vertical inhibition of the BRAFV600E-MEK-ERK cascade and delineates how elevated cellular BRAF concentrations generate drug resistance to dabrafenib and trametinib. In addition, the computational simulations suggest that elevated ATP levels could be a factor in drug resistance to dabrafenib. The mathematical model that is developed in this study will have generic application in the improved design of anticancer combination therapies that target BRAF-MEK-ERK pathways.

scholarly journals Quantitative regulation of the dynamic steady state of actin networks

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Angelika Manhart ◽  
Téa Aleksandra Icheva ◽  
Christophe Guerin ◽  
Tobbias Klar ◽  
Rajaa Boujemaa-Paterski ◽  
...  
Keyword(s):  
Mathematical Model ◽  
Steady State ◽  
Heterogeneous Networks ◽  
In Silico ◽  
Actin Network ◽  
Network Nodes ◽  
Actin Networks ◽  
Cell Functions ◽  
Selective Disassembly

Principles of regulation of actin network dimensions are fundamentally important for cell functions, yet remain unclear. Using both in vitro and in silico approaches, we studied the effect of key parameters, such as actin density, ADF/Cofilin concentration and network width on the network length. In the presence of ADF/Cofilin, networks reached equilibrium and became treadmilling. At the trailing edge, the network disintegrated into large fragments. A mathematical model predicts the network length as a function of width, actin and ADF/Cofilin concentrations. Local depletion of ADF/Cofilin by binding to actin is significant, leading to wider networks growing longer. A single rate of breaking network nodes, proportional to ADF/Cofilin density and inversely proportional to the square of the actin density, can account for the disassembly dynamics. Selective disassembly of heterogeneous networks by ADF/Cofilin controls steering during motility. Our results establish general principles on how the dynamic steady state of actin network emerges from biochemical and structural feedbacks.

scholarly journals In Vivo Microscopic Observations of Vasoactive Drugs and Platelet Aggregation

1977 ◽  
Author(s):  
Mary P. Wiedeman ◽  
Ronald F. Turna ◽  
Harvey N. Mayrovitz
Keyword(s):  
Platelet Aggregation ◽  
In Vivo Studies ◽  
Vasoactive Drugs ◽  
Platelet Activity ◽  
Experimental Site ◽  
Vasodilator Drugs ◽  
Platelet Aggregate ◽  
Bat Wing

A survey of the literature concerning the effect of vasoactive drugs on platelet aggregation would support the generalization that, vasoconstrictors enhance platelet aggregation while vasodilators inhibit the action. Some of the information comes from in vitro studies and some from in vivo studies. Using the bat wing as the experimental site, microscopic observation of the effect of intra-arterial injections of vasoconstrictor drugs (epinephrine and serotonin) and vasodilator drugs (dipyridamole and phenoxybenzamine) confirmed the concept. Platelet activity induced by laser beam after administration of vasoconstrictors showed an increased response while vasodilator drugs produced the converse. In addition, denervated vessels showed diminished activity in platelet aggregate formation. Experimental procedures and responses will be shown by cinemicrophotography.

scholarly journals Antiaggregatory activity of new 1-ethylxanthine cyclohexylammonium salt in vitro

2013 ◽  
Vol 94 (5) ◽  
pp. 692-695
Author(s):  
F Kh Kamilov ◽  
G A Timirkhanova ◽  
A I Samorodova ◽  
A V Samorodov ◽  
F A Khaliullin ◽  
...  
Keyword(s):  
Acetic Acid ◽  
Platelet Aggregation ◽  
Aggregate Size ◽  
Adenosine Diphosphate ◽  
Biochemical Effect ◽  
Platelet Aggregate ◽  
Antiaggregatory Activity ◽  
The Impact ◽  
Induced Aggregation

Aim. To study the biochemical effect on hemostasis of a new cyclohexilammonium salt of 2-[1-ethyl-3-methyl-7(dioxotiethanyl-3)xantinyl-8-thio]acetic acid in vitro. Methods. Thromboelastography was performed using the citrate blood samples of healthy male donors. Global hemostatic effect, fibrinogen and platelet function, fibrinolysis and clot strength, and stability were analyzed at thromboelastography. The impact of firstly synthesized xantine derivative and pentoxifylline on the functional activity of platelets in vitro was studied using a laser analyzer of platelet aggregation. Adenosine diphosphate, collagen, epinephrine and ristocetin induced clotting were registered. General clotting characteristics, maximal aggregation values, maximal aggregation speed, mean platelet aggregate size, activity of platelet-derived factor 3, level of platelet-derived factor 4 were measured. Release of platelet-derived factors 3 and 4 at platelet aggregation were assessed after adenosinediphosphate-induced aggregation and centrifugation. Results. Cyclohexylammonium salt of 2-[1-ethyl-3-methyl-7-(dioxotiethanyl-3)xantinyl-8-thio]acetic acid in vitro showed antiaggregatory activity that exceeds such of pentoxifylline. It has been revealed that the second platelet aggregation wave, that is induced by small dose of adenosinediphosphate, is absent in the presence of the new cyclohexylammonium salt, lag-period in collagen-induced platelet aggregation elongates, and availability and release of platelet-derived factors 3 and 4 decreases. Conclusion. The research findings show potentially high antiaggregatory activity of 2-[1-ethyl-3-methyl-7-(dioxotiethanyl-3)xantinyl-8-thio]acetic acid cyclohexylammonium salt as an inhibitor of platelet release reaction.

Platelet Aggregation Induced In Vivo By Heparin And Heparin Fractions

1981 ◽  
Author(s):  
M Silane ◽  
J N Lindon ◽  
B J Ransil ◽  
R D Rosenberg ◽  
E W Salzman
Keyword(s):  
Molecular Weight ◽  
Platelet Aggregation ◽  
Reciprocal Relationship ◽  
Low Molecular Weight ◽  
Arterial Blood ◽  
Platelet Aggregate ◽  
Heparin Fractions ◽  
Platelet Aggregates

As we have reported, heparin-induced platelet aggregation in vitro varies among heparin subfractions, being generally less with lower molecular weights and having a reciprocal relationship with antithrombin affinity.We now have studied heparin-induced platelet aggregates in vivo by the technique of Wu and Hoak using arterial blood from unanesthetized rabbits. Porcine mucosal heparin was fractionated by gel filtration into high molecular weight (ave. 15,000 Daltons) or low molecular weight (ave. 6,000 Daltons) preparations. IV administration of commercial porcine mucosal heparin (spec. act. 150 u/mg) or high (spec. act. 183 u/mg) or low (spec. act. 208 u/mg) molecular weight fractions was followed by an increase in the platelet aggregate ratio compared with preinjection control values. The rise in platelet aggregate ratio with heparin was significantly different from the effect of a saline placebo (n=8) but was not significantly different among rabbits receiving the commercial heparin (n=9) or the high (n=8) or low (n=8) molecular weight preparations. Peak rise in circulating aggregate ratio occurred 2 minutes after the injection, and values returned to control levels within 15 to 30 minutes. There was no change in platelet count in blood collected in EDTA, suggesting that the aggregates were not removed from the circulation in vivo.Heparin fractions of low molecular weight were further separated according to antithrombin affinity by an antithrombin binding technique. In 8 rabbits low molecular weight/high antithrombin affinity heparin (spec. act. 480 u/mg) did not cause formation of platelet aggregates. The results were significantly different from those with commercial heparin (p=0.05) or with the other heparin fractions (p=0.06).Clinical use of low molecular weight heparin of high antithrombin affinity may lead to fewer heparin-induced platelet effects and to an improvement in anticoagulant therapy.

scholarly journals Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation

Blood ◽  
1985 ◽  
Vol 66 (2) ◽  
pp. 282-286 ◽  
Author(s):  
HI Saba ◽  
SR Saba ◽  
J Dent ◽  
ZM Ruggeri ◽  
TS Zimmerman
Keyword(s):  
Platelet Aggregation ◽  
Von Willebrand Factor ◽  
Von Willebrand Disease ◽  
New Variant ◽  
Platelet Aggregate ◽  
Spontaneous Platelet Aggregation ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract Type IIB von Willebrand disease is characterized by enhanced ristocetin- induced platelet aggregation and absence of large von Willebrand factor multimers from plasma. An alteration of the von Willebrand factor molecule resulting in increased reactivity with platelets appears to be the basis for these abnormalities. We have now identified a new variant of type IIB von Willebrand disease in a family in which the four affected members also have chronic thrombocytopenia, in vivo platelet aggregate formation, and spontaneous platelet aggregation in vitro. In spite of repeatedly prolonged bleeding times and persistent thrombocytopenia, their bleeding diathesis is only moderate.

Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling

Blood ◽  
2005 ◽  
Vol 106 (9) ◽  
pp. 3028-3034 ◽  
Author(s):  
Nisha Nanda ◽  
Patrick Andre ◽  
Ming Bao ◽  
Karl Clauser ◽  
Francis Deguzman ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Adhesion Molecules ◽  
Lymphocyte Activation ◽  
Aggregate Stability ◽  
Family Interactions ◽  
Adapter Proteins ◽  
Platelet Aggregate ◽  
Slam Family

AbstractPlatelet aggregation is a dynamic entity, capable of directing its own growth and stability via the activation of signaling cascades that lead to the expression and secretion of various secondary agonists. Here we show that the signaling pathways triggered during platelet aggregation include an intrinsic pro-thrombotic activity mediated by 2 homophilic adhesion molecules, CD84 and CD150 (SLAM [signaling lymphocyte activation molecule]), which are tyrosine phosphorylated in a platelet aggregation–dependent fashion. The 2 CD84/SLAM adapter proteins, SAP (SLAM-associated protein) and EAT-2 (EWS-activated transcript-2), were found in platelets; only SAP, however, was found to immunoprecipitate with tyrosine-phosphorylated SLAM. The immobilized extracellular domain of CD84 promoted microaggregate formation, while SAP-deficient platelets demonstrated defective spreading on immobilized CD84, demonstrating a functional role in platelets for SLAM family interactions. Finally, analysis of SLAM-deficient mice revealed an overall defect in platelet aggregation in vitro and a delayed arterial thrombotic process in vivo. The data indicate that signaling of the adhesion molecules in the SLAM family, activated by proximity during aggregation, further stabilize platelet-platelet interactions in thrombosis.

Mathematical model of steroidogenesis in rat and rabbit testes

1980 ◽  
Vol 239 (1) ◽  
pp. R184-R195
Author(s):  
S. Becker ◽  
C. Chubb ◽  
L. Ewing
Keyword(s):  
Mathematical Model ◽  
Steady State ◽  
Transition Probabilities ◽  
Model Construction ◽  
Steroid Secretion ◽  
Testicular Steroidogenesis ◽  
Testosterone Biosynthesis ◽  
Testicular Steroids ◽  
Secretion Rates

The purpose of this study was to develop a mathematical model of testicular steroidogenesis which could not only predict steroid secretion but also could be implemented to test the validity of assumptions used in studies of testicular testosterone biosynthesis in rats and rabbits. Since the two predominant fates of testicular steroids are metabolism and secretion, we hypothesized that the data for construction of the model could be observed testicular steroid secretions and that these data could then be used to elucidate intratesticular steroid conversions. Equations based on steroid secretion by testes perfused in vitro were developed to estimate transition probabilities corresponding to steroid secretion or conversion. The model was tested by comparing the predicted steroid secretion rates with those observed for control testes perfused in vitro. In addition, the transition probabilities determined by the model were used to indicate the predominant series of reactions for converting pregnenolone to testosterone. The results presented herein confirm the capability of the model to predict steroid secretion rates and to predict preferred pathways for testosterone biosynthesis in maximally stimulated testes perfused in vitro. Moreover, the model construction required only algebra and steady-state measurements.

Sign in / Sign up

Export Citation Format

Share Document